Switching Between Reference Biologics and Biosimilars for the Treatment of Rheumatology, Gastroenterology, and Dermatology Inflammatory Conditions: Considerations for the Clinician
Crossref DOI link: https://doi.org/10.1007/s11926-017-0658-4
Published Online: 2017-06-16
Published Print: 2017-06
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Moots, Robert
Azevedo, Valderilio
Coindreau, Javier L.
Dörner, Thomas
Mahgoub, Ehab
Mysler, Eduardo
Scheinberg, Morton
Marshall, Lisa
Funding for this research was provided by:
Pfizer
License valid from 2017-06-01